175 related articles for article (PubMed ID: 36810001)
1. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
Shi Q; Yu J; Liu D; Ren F; Wu J; Shen K
BMC Cancer; 2023 Feb; 23(1):173. PubMed ID: 36810001
[TBL] [Abstract][Full Text] [Related]
2. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
4. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
Li JJ; Yu Y; Ge J
Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and prognosis of patients with HER2-low breast cancer.
Yang X; Li Y; Lu X; Ren X; Hua B
BMC Cancer; 2023 Sep; 23(1):914. PubMed ID: 37770874
[TBL] [Abstract][Full Text] [Related]
6. New insights into HER2-low breast cancer brain metastasis: A retrospective analysis.
Xu H; Wang Y; Li L; Han Y; Wu Y; Sa Q; Xu B; Wang J
Breast; 2024 Feb; 73():103669. PubMed ID: 38176304
[TBL] [Abstract][Full Text] [Related]
7. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer.
Jin J; Li B; Cao J; Li T; Zhang J; Cao J; Zhao M; Wang L; Wang B; Tao Z; Hu X
J Transl Med; 2023 Jun; 21(1):360. PubMed ID: 37264417
[TBL] [Abstract][Full Text] [Related]
8. Evolution of low HER2 expression between early and advanced-stage breast cancer.
Tarantino P; Gandini S; Nicolò E; Trillo P; Giugliano F; Zagami P; Vivanet G; Bellerba F; Trapani D; Marra A; Esposito A; Criscitiello C; Viale G; Curigliano G
Eur J Cancer; 2022 Mar; 163():35-43. PubMed ID: 35032815
[TBL] [Abstract][Full Text] [Related]
9. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer.
Chen M; Chen W; Liu D; Chen W; Shen K; Wu J; Zhu L
Breast Cancer; 2022 Sep; 29(5):844-853. PubMed ID: 35729304
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
12. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer.
Shiino S; Kinoshita T; Yoshida M; Jimbo K; Asaga S; Takayama S; Tsuda H
Clin Breast Cancer; 2016 Aug; 16(4):e133-40. PubMed ID: 27268749
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics, tumor-infiltrating lymphocytes, and prognosis in HER2-low breast cancer: A comparison study with HER2-zero and HER2-positive disease.
Lu Y; Tong Y; Fei X; Chen X; Shen K
Cancer Med; 2023 Aug; 12(15):16264-16278. PubMed ID: 37366301
[TBL] [Abstract][Full Text] [Related]
16. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
17. HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases.
Cai M; Li M; Lv H; Zhou S; Xu X; Shui R; Yang W
BMC Cancer; 2023 Jul; 23(1):656. PubMed ID: 37442945
[TBL] [Abstract][Full Text] [Related]
18. An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer.
Hui T; Li S; Wang H; Ma X; Du F; Gao W; Yang S; Sang M; Li Z; Ding R; Liu Y; Geng C
Oncologist; 2023 Dec; 28(12):e1160-e1169. PubMed ID: 37279952
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
20. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]